Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Molecularly targeted therapies for p53-mutant cancers.

Zhao D, Tahaney WM, Mazumdar A, Savage MI, Brown PH.

Cell Mol Life Sci. 2017 Nov;74(22):4171-4187. doi: 10.1007/s00018-017-2575-0. Epub 2017 Jun 22. Review.

PMID:
28643165
2.

Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA.

Lu W, Cheng F, Yan W, Li X, Yao X, Song W, Liu M, Shen X, Jiang H, Chen J, Li J, Huang J.

Oncogene. 2017 Aug 17;36(33):4719-4731. doi: 10.1038/onc.2017.41. Epub 2017 Apr 10.

3.

Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.

Chen Z, Wang L, Yao D, Yang T, Cao WM, Dou J, Pang JC, Guan S, Zhang H, Yu Y, Zhao Y, Wang Y, Xu X, Shi Y, Patel R, Zhang H, Vasudevan SA, Liu S, Yang J, Nuchtern JG.

Sci Rep. 2016 Dec 19;6:38011. doi: 10.1038/srep38011.

4.

Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex.

Carrà G, Crivellaro S, Taulli R, Guerrasio A, Saglio G, Morotti A.

Int J Mol Sci. 2016 Nov 29;17(12). pii: E1997. Review.

5.

Synthetic lethality in lung cancer and translation to clinical therapies.

Leung AW, de Silva T, Bally MB, Lockwood WW.

Mol Cancer. 2016 Sep 29;15(1):61. Review.

6.

Oncogenic Intra-p53 Family Member Interactions in Human Cancers.

Ferraiuolo M, Di Agostino S, Blandino G, Strano S.

Front Oncol. 2016 Mar 31;6:77. doi: 10.3389/fonc.2016.00077. eCollection 2016. Review.

7.

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

Bogen SL, Pan W, Gibeau CR, Lahue BR, Ma Y, Nair LG, Seigel E, Shipps GW Jr, Tian Y, Wang Y, Lin Y, Liu M, Liu S, Mirza A, Wang X, Lipari P, Seidel-Dugan C, Hicklin DJ, Bishop WR, Rindgen D, Nomeir A, Prosise W, Reichert P, Scapin G, Strickland C, Doll RJ.

ACS Med Chem Lett. 2016 Jan 20;7(3):324-9. doi: 10.1021/acsmedchemlett.5b00472. eCollection 2016 Mar 10.

8.

RY10-4 Inhibits the Proliferation of Human Hepatocellular Cancer HepG2 Cells by Inducing Apoptosis In Vitro and In Vivo.

Zhang X, Wang Y, Han S, Xiang H, Peng Y, Wu Y, Pan S, Zhang Y, Ruan J.

PLoS One. 2016 Mar 14;11(3):e0151679. doi: 10.1371/journal.pone.0151679. eCollection 2016.

9.

USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation.

Mungamuri SK, Qiao RF, Yao S, Manfredi JJ, Gu W, Aaronson SA.

Cell Rep. 2016 Mar 22;14(11):2528-37. doi: 10.1016/j.celrep.2016.02.049. Epub 2016 Mar 10.

10.

Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.

Karan G, Wang H, Chakrabarti A, Karan S, Liu Z, Xia Z, Gundluru M, Moreton S, Saunthararajah Y, Jackson MW, Agarwal MK, Wald DN.

Mol Cancer Ther. 2016 Apr;15(4):574-582. doi: 10.1158/1535-7163.MCT-15-0467. Epub 2016 Feb 16.

11.

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.

Hiraki M, Hwang SY, Cao S, Ramadhar TR, Byun S, Yoon KW, Lee JH, Chu K, Gurkar AU, Kolev V, Zhang J, Namba T, Murphy ME, Newman DJ, Mandinova A, Clardy J, Lee SW.

Chem Biol. 2015 Sep 17;22(9):1206-16. doi: 10.1016/j.chembiol.2015.07.016. Epub 2015 Aug 27.

12.

p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation.

Ou Y, Wang SJ, Jiang L, Zheng B, Gu W.

J Biol Chem. 2015 Jan 2;290(1):457-66. doi: 10.1074/jbc.M114.616359. Epub 2014 Nov 17.

13.

p53 Family and Cellular Stress Responses in Cancer.

Pflaum J, Schlosser S, Müller M.

Front Oncol. 2014 Oct 21;4:285. doi: 10.3389/fonc.2014.00285. eCollection 2014. Review.

14.

Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.

Taguchi A, Delgado O, Celiktaş M, Katayama H, Wang H, Gazdar AF, Hanash SM.

Proteomics. 2014 Dec;14(23-24):2750-9. doi: 10.1002/pmic.201400378. Epub 2014 Nov 20.

15.

High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activity.

Garufi A, D'Orazi G.

J Exp Clin Cancer Res. 2014 Sep 27;33:79. doi: 10.1186/s13046-014-0079-4.

16.

Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters.

Mungamuri SK, Wang S, Manfredi JJ, Gu W, Aaronson SA.

Oncogene. 2015 May 7;34(19):2461-70. doi: 10.1038/onc.2014.198. Epub 2014 Jul 14.

17.

MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation.

Shostak K, Patrascu F, Göktuna SI, Close P, Borgs L, Nguyen L, Olivier F, Rammal A, Brinkhaus H, Bentires-Alj M, Marine JC, Chariot A.

Cell Death Differ. 2014 May;21(5):811-24. doi: 10.1038/cdd.2014.2. Epub 2014 Jan 31.

18.

A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.

Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D'Orazi V, Avantaggiati M, Crispini A, Pucci D, D'Orazi G.

J Exp Clin Cancer Res. 2013 Oct 7;32:72. doi: 10.1186/1756-9966-32-72.

19.

USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.

Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y, Zhang H, Shohet JM, Nuchtern JG, Kim ES, Yang J.

Cell Death Dis. 2013 Oct 17;4:e867. doi: 10.1038/cddis.2013.400.

20.

p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes.

Benson EK, Mungamuri SK, Attie O, Kracikova M, Sachidanandam R, Manfredi JJ, Aaronson SA.

Oncogene. 2014 Jul 24;33(30):3959-69. doi: 10.1038/onc.2013.378. Epub 2013 Oct 7.

Supplemental Content

Support Center